Gut Bacteria Predict Melanoma Recurrence

Scientists have discovered that the types and amounts of certain bacteria in the gut can predict the likelihood of melanoma recurrence after surgery and immunotherapy. The research, involving 674 melanoma patients from a global clinical trial, found that specific gut bacterial groups accurately signaled recurrence risk in up to 94 percent of cases.

These identified bacterial markers interact with immune cells and can alter a patient's response to treatments like nivolumab and ipilimumab. This discovery offers a potential way to tailor treatments for melanoma patients by analyzing their unique gut microbiome before therapy begins.

Crucially, the study highlighted that these predictive bacterial signatures are not universal and differ based on geographic origin. For instance, bacterial fingerprints found to be accurate predictors in North American patients might only predict recurrence in patients from other regions if they share similar microbial profiles.

Researchers anticipate that analyzing a patient's microbiome in the future will provide more reliable prognoses, guiding treatment decisions from the outset and improving patient outcomes. The findings were published in the journal Cell by researchers from NYU Langone Health and its Perlmutter Cancer Center.